AWCI
CRSP icon

Alpine Woods Capital Investors’s CRISPR Therapeutics CRSP Stock Holding History

Alpine Woods Capital Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,220
Closed -$391K – 227
2026
Q1 		$391K Buy
8,220
+135
+2% +$7.12K 0.09% 125
2025
Q4 		$424K Sell
8,085
-194
-2% -$11.6K 0.1% 138
2025
Q3 		$537K Sell
8,279
-222
-3% -$12.7K 0.12% 108
2025
Q2 		$413K Buy
8,501
+1,851
+28% +$71.6K 0.1% 124
2025
Q1 		$226K Sell
6,650
-335
-5% -$14.2K 0.06% 148
2024
Q4 		$275K Buy
6,985
+1,255
+22% +$59.3K 0.05% 164
2024
Q3 		$314K Buy
+5,730
New +$291K 0.06% 160
2022
Q1 		– Sell
-42,766
Closed -$3.24M – 216
2021
Q4 		$3.24M Sell
42,766
-24,900
-37% -$2.18M 0.32% 98
2021
Q3 		$7.57M Buy
67,666
+139
+0.2% +$17.5K 0.81% 40
2021
Q2 		$10.9M Buy
67,527
+27,899
+70% +$3.39M 1.13% 21
2021
Q1 		$4.83M Buy
39,628
+4,434
+13% +$670K 0.54% 65
2020
Q4 		$5.39M Buy
35,194
+6,886
+24% +$814K 0.66% 54
2020
Q3 		$2.37M Buy
28,308
+3,262
+13% +$289K 0.36% 92
2020
Q2 		$1.84M Buy
25,046
+10,897
+77% +$637K 0.35% 86
2020
Q1 		$600K Buy
14,149
+4,040
+40% +$209K 0.13% 151
2019
Q4 		$616K Sell
10,109
-49
-0.5% -$2.67K 0.12% 159
2019
Q3 		$416K Hold
10,158
– – 0.08% 181
2019
Q2 		$478K Hold
10,158
– – 0.1% 186
2019
Q1 		$363K Hold
10,158
– – 0.08% 205
2018
Q4 		$290K Buy
10,158
+43
+0.4% +$1.5K 0.07% 219
2018
Q3 		$449K Buy
+10,115
New +$530K 0.09% 164

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Alpine Woods Capital Investors's CRSP Position: Q2 2026 in Review

Alpine Woods Capital Investors sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 8,220 shares — an estimated $391K sold.

Alpine Woods Capital Investors first reported a position in CRSP in Q3 2018 and held it in 21 quarters. The position peaked at $10.9M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Alpine Woods Capital Investors reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Alpine Woods Capital Investors sold 8,220 CRISPR Therapeutics shares in Q2 2026, an estimated $391K.
  • Alpine Woods Capital Investors first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 21 quarters.
  • Alpine Woods Capital Investors's CRISPR Therapeutics position peaked at $10.9M in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2026, filed 7 Aug 2026.